Josua Lottering, a young patient from South Africa, embarked on a significant journey to Dhaka, Bangladesh, with his mother. Despite battling severe coughing spasms due to cystic fibrosis, Josua’s trip aimed to procure a year’s supply of a groundbreaking medication.
The drug in question, Trikafta, is developed by Vertex Pharmaceuticals, a Boston-based company. Trikafta has revolutionized the treatment of cystic fibrosis, allowing patients to breathe more easily and extend their lifespans. The price for a year’s supply in the United States reaches approximately $346,000.
Vertex maintains a monopoly in the realm of transformative cystic fibrosis drugs. Since its launch in 2019, Trikafta has generated $49 billion in revenue. However, the company has not registered the medication in numerous lower-income countries. Additionally, Vertex has actively impeded attempts to produce affordable generic versions, a common practice among pharmaceutical firms aiming to protect high prices in affluent markets.
A Bangladeshi company has now circumvented these barriers by reverse engineering Trikafta. This has been possible through a strategic exploitation of global patent law, allowing the sale of a cheaper variant named Triko.
Recently, the Lotterings, alongside other cystic fibrosis patients and their families, traveled to Dhaka to purchase Triko from Beximco Pharmaceuticals. The availability of this generic drug provides a vital option for families who struggle to afford the exorbitant costs in their home countries.
Leave a Reply